AstraZeneca to conduct Phase II study for olaparib

The battle against cancer seems to be on the verge of a major step forward. The success of a new class of drugs “PARP inhibitors” in destroying the disease points to a new direction in the development of anticancer drugs.

AstraZeneca said on February 11 that it will conduct its Phase IIa study for olaparib (Study 39), a novel, orally active PARP inhibitor that induces synthetic lethality in ...